The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Uterine Neoplasms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Uterine Neoplasms


High impact information on Uterine Neoplasms


Chemical compound and disease context of Uterine Neoplasms

  • The nuclear receptor for the female hormone progesterone (PR) is widely expressed in uterine cancer [11].
  • Estrogen has many beneficial cardiovascular actions although concerns have been raised about its effects on the progression of breast and uterine neoplasms and its tendency to increase coagulability [12].
  • From 1970 through 1986, 219 women received postoperative pelvic external beam therapy and vaginal radium or cesium for uterine cancer [13].
  • Clomiphene may increase uterine cancer risk, with higher doses leading to higher risk [14].
  • OBJECTIVE: EM-652 is a pure antiestrogen in human breast and uterine cancer cells that also reduces bone loss and plasma lipid levels in the rat [15].

Biological context of Uterine Neoplasms


Anatomical context of Uterine Neoplasms


Gene context of Uterine Neoplasms


Analytical, diagnostic and therapeutic context of Uterine Neoplasms


  1. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. Ragaz, J., Coldman, A. J. Clin. Oncol. (1998) [Pubmed]
  2. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Yakirevich, E., Sabo, E., Lavie, O., Mazareb, S., Spagnoli, G.C., Resnick, M.B. Clin. Cancer Res. (2003) [Pubmed]
  3. Cancer risk after renal transplantation in Japan. Hoshida, Y., Tsukuma, H., Yasunaga, Y., Xu, N., Fujita, M.Q., Satoh, T., Ichikawa, Y., Kurihara, K., Imanishi, M., Matsuno, T., Aozasa, K. Int. J. Cancer (1997) [Pubmed]
  4. Causes of infertility as predictors of subsequent cancer risk. Brinton, L.A., Westhoff, C.L., Scoccia, B., Lamb, E.J., Althuis, M.D., Mabie, J.E., Moghissi, K.S. Epidemiology (Cambridge, Mass.) (2005) [Pubmed]
  5. Platinum/oral etoposide therapy in non-small cell lung cancer. Furuse, K. Oncology (1992) [Pubmed]
  6. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. Fisher, B., Costantino, J.P., Redmond, C.K., Fisher, E.R., Wickerham, D.L., Cronin, W.M. J. Natl. Cancer Inst. (1994) [Pubmed]
  7. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Venn, A., Watson, L., Bruinsma, F., Giles, G., Healy, D. Lancet (1999) [Pubmed]
  8. Clinical effects of raloxifene hydrochloride in women. Khovidhunkit, W., Shoback, D.M. Ann. Intern. Med. (1999) [Pubmed]
  9. PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Radu, A., Neubauer, V., Akagi, T., Hanafusa, H., Georgescu, M.M. Mol. Cell. Biol. (2003) [Pubmed]
  10. Mutations in the BRCA1-associated RING domain (BARD1) gene in primary breast, ovarian and uterine cancers. Thai, T.H., Du, F., Tsan, J.T., Jin, Y., Phung, A., Spillman, M.A., Massa, H.F., Muller, C.Y., Ashfaq, R., Mathis, J.M., Miller, D.S., Trask, B.J., Baer, R., Bowcock, A.M. Hum. Mol. Genet. (1998) [Pubmed]
  11. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Arnett-Mansfield, R.L., deFazio, A., Wain, G.V., Jaworski, R.C., Byth, K., Mote, P.A., Clarke, C.L. Cancer Res. (2001) [Pubmed]
  12. Phytoestrogens and cardiovascular health. Lissin, L.W., Cooke, J.P. J. Am. Coll. Cardiol. (2000) [Pubmed]
  13. Enteric morbidity of postoperative pelvic external beam and brachytherapy for uterine cancer. Potish, R.A., Dusenbery, K.E. Int. J. Radiat. Oncol. Biol. Phys. (1990) [Pubmed]
  14. Uterine cancer after use of clomiphene citrate to induce ovulation. Althuis, M.D., Moghissi, K.S., Westhoff, C.L., Scoccia, B., Lamb, E.J., Lubin, J.H., Brinton, L.A. Am. J. Epidemiol. (2005) [Pubmed]
  15. The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity. Lemieux, C., Picard, F., Labrie, F., Richard, D., Deshaies, Y. Obes. Res. (2003) [Pubmed]
  16. Frequent occurrence of p53 gene mutations in uterine cancers at advanced clinical stage and with aggressive histological phenotypes. Tsuda, H., Hirohashi, S. Jpn. J. Cancer Res. (1992) [Pubmed]
  17. Cigarette smoking and pregnancy I: ovarian, uterine and placental effects. Shiverick, K.T., Salafia, C. Placenta (1999) [Pubmed]
  18. Potential criteria for cohort selection in chemoprevention trials of uterine adenocarcinoma. Baker, V.V. J. Cell. Biochem. Suppl. (1995) [Pubmed]
  19. A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT. Ganiatsas, S., Dow, R., Thompson, A., Schulman, B., Germain, D. Oncogene (2001) [Pubmed]
  20. Compartmentalized uterotrophic effects of tamoxifen, toremifene, and estradiol in the ovariectomized Wistar (Han) rat. Carthew, P., Edwards, R.E., Nolan, B.M., Tucker, M.J., Smith, L.L. Toxicol. Sci. (1999) [Pubmed]
  21. Recurring chemotherapy-associated alopecia areata: case report and literature review. Motl, S.E., Fausel, C. Pharmacotherapy (2003) [Pubmed]
  22. Telomeric association in women with breast and uterine cervix cancer. Paz-y-Miño, C., Sánchez, M.E., Del Pozo, M., Baldeón, M.A., Córdova, A., Gutiérrez, S., Peñaherrera, M.S., Neira, M., Ocampo, L., Leone, P.E. Cancer Genet. Cytogenet. (1997) [Pubmed]
  23. A putative growth factor in extract from uterine cancers. Matsunami, K., Imai, A., Tamaya, T. Res. Commun. Chem. Pathol. Pharmacol. (1989) [Pubmed]
  24. Mutation screening of MSH2 and MLH1 mRNA in hereditary non-polyposis colon cancer syndrome. Froggatt, N.J., Brassett, C., Koch, D.J., Evans, D.G., Hodgson, S.V., Ponder, B.A., Maher, E.R. J. Med. Genet. (1996) [Pubmed]
  25. HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Singer, G., Kurman, R.J., McMaster, M.T., Shih, I.e.M. Am. J. Surg. Pathol. (2002) [Pubmed]
  26. AKT involvement in cisplatin chemoresistance of human uterine cancer cells. Gagnon, V., Mathieu, I., Sexton, E., Leblanc, K., Asselin, E. Gynecol. Oncol. (2004) [Pubmed]
  27. Intravenous leiomyomatosis of the uterus with multiple pulmonary metastases associated with large bullae-like cyst formation. Matsumoto, K., Yamamoto, T., Hisayoshi, T., Asano, G. Pathol. Int. (2001) [Pubmed]
  28. Isoenzymes of hexokinase, 6-phosphogluconate dehydrogenase, phosphoglucomutase and lactate dehydrogenase in uterine cancer. Marshall, M.J., Neal, F.E., Goldberg, D.M. Br. J. Cancer (1979) [Pubmed]
  29. The effects of Provera on chemotherapy of uterine cancer cell lines. Nguyen, H.N., Sevin, B.U., Averette, H.E., Perras, J., Ramos, R., Penalver, M., Donato, D. Gynecol. Oncol. (1991) [Pubmed]
  30. Tamoxifen and malignant epithelial-nonepithelial tumours of the endometrium: report of six cases and review of the literature. Treilleux, T., Mignotte, H., Clement-Chassagne, C., Guastalla, P., Bailly, C. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. (1999) [Pubmed]
  31. Phytoestrogens as cardioprotective agents. Park, D., Huang, T., Frishman, W.H. Cardiology in review. (2005) [Pubmed]
  32. Effect control of HDR afterloading radiation in uterine cancer by NMR imaging with and without GD-DTPA. Roth, G. Sonderbände zur Strahlentherapie und Onkologie. (1988) [Pubmed]
  33. Image-based intracavitary brachytherapy in the treatment of inoperable uterine cancer: individual dose specification at specific anatomical sites. Kim, R.Y., Falkenberg, E., Pareek, P. Brachytherapy. (2005) [Pubmed]
WikiGenes - Universities